Evidence map›Paper›PMID 37663052›Full record

ArticleGeneral psychiatry2023

Neuro-11: a new questionnaire for the assessment of somatic symptom disorder in general hospitals.

Silin Zeng, Yian Yu, Shan Lu, Sirui Zhang, Xiaolin Su, Ge Dang, Ying Liu, Zhili Cai, Siyan Chen, Yitao He and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in General psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Silin Zeng *Department of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Yian Yu *Department of Statistics and Data Science, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Shan LuInstitute of Neurological Diseases, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.ORCID 0000-0001-7297-5649
Sirui ZhangDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Xiaolin SuDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Ge DangDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Ying LiuDepartment of neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zhili CaiDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Siyan ChenDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Yitao HeDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Xin JiangDepartment of Geriatrics, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, China.
Chanjuan ChenDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Lei YuanDepartment of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Peng XieNHC Key Laboratory of Diagnosis and Treatment on First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
Jianqing Shi *Department of Statistics and Data Science, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Qingshan Geng *Department of Geriatrics, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, China.
Rafael H Llinas *Department of neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yi Guo *Department of Neurology, Shenzhen People's Hospital,The second Affiliated Hospitals of Jinan University, The first Affiliated Hospitals of Southern University of Science and Technology, Shenzhen, Guangdong, China.
Jinan University · CNJohns Hopkins University · USSouthern University of Science and Technology · CNShenzhen Bay Laboratory · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Somatic symptom disorder (SSD) commonly presents in general hospital settings, posing challenges for healthcare professionals lacking specialised psychiatric training. The Neuro-11 Neurosis Scale (Neuro-11) offers promise in screening and evaluating psychosomatic symptoms, comprising 11 concise items across three dimensions: somatic symptoms, negative emotions and adverse events. Prior research has validated the scale's reliability, validity and theoretical framework in somatoform disorders, indicating its potential as a valuable tool for SSD screening in general hospitals. Aims: This study aimed to establish the reliability, validity and threshold of the Neuro-11 by comparing it with standard questionnaires commonly used in general hospitals for assessing SSD. Through this comparative analysis, we aimed to validate the effectiveness and precision of the Neuro-11, enhancing its utility in clinical settings. Methods: Between November 2020 and December 2021, data were collected from 731 patients receiving outpatient and inpatient care at Shenzhen People's Hospital in China for various physical discomforts. The patients completed multiple questionnaires, including the Neuro-11, Short Form 36 Health Survey, Patient Health Questionnaire 15 items, Hamilton Anxiety Scale and Hamilton Depression Scale. Psychiatry-trained clinicians conducted structured interviews and clinical examinations to establish a gold standard diagnosis of SSD. Results: The Neuro-11 demonstrated strong content reliability and structural consistency, correlating significantly with internationally recognised and widely used questionnaires. Despite its brevity, the Neuro-11 exhibited significant correlations with other questionnaires. A test-retest analysis yielded a correlation coefficient of 1.00, Spearman-Brown coefficient of 0.64 and Cronbach's α coefficient of 0.72, indicating robust content reliability and internal consistency. Confirmatory factor analysis confirmed the validity of the three-dimensional structure (p<0.001, comparative fit index=0.94, Tucker-Lewis index=0.92, root mean square error of approximation=0.06, standardised root mean square residual=0.04). The threshold of the Neuro-11 is set at 10 points based on the maximum Youden's index from the receiver operating characteristic curve analysis. In terms of diagnostic efficacy, the Neuro-11 has an area under the curve of 0.67. Conclusions: (1) The Neuro-11 demonstrates robust associations with standard questionnaires, supporting its validity. It is applicable in general hospital settings, assessing somatic symptoms, negative emotions and adverse events. (2) The Neuro-11 exhibits strong content reliability and validity, accurately capturing the intended constructs. The three-dimensional structure demonstrates robust construct validity. (3) The threshold of the Neuro-11 is set at 10 points.

Indexed as

neuropsychiatryneuropsychological tests

Identifiers

PMID37663052
PMCPMC10471855
OpenAlexW4386295969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.